Growth factor signalling in prostatic growth: Significance in tumour development and therapeutic targeting

British Journal of Pharmacology

Volumn 147, Issue SUPPL. 2, 2006, Pages

  Reynolds, Arich Ryan ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Anoikis; Apoptosis; FGF; Growth factor signalling; Hypoxia; IGF 1; Prostate cancer; TGF ; VEGF

Indexed keywords

ANVIRIZEL; CARDIAC GLYCOSIDE; DOXAZOSIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; MONOCLONAL ANTIBODY; ROSIGLITAZONE; SOMATOMEDIN C; TAMSULOSIN; TERAZOSIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONFERENCE PAPER; DRUG MECHANISM; DRUG TARGETING; HUMAN; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR GROWTH; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 32544439571     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706635     Document Type: Conference Paper

References (102)

1. ATTWELL, S., ROSKELLEY, C., MILLS, J., TROUSSARD, A., WU, C. & DEDHAR, S. (2003). The integrin-linked kinase (ILK) suppresses anoikis. Oncogene, 19, 3811-3815.
2. BASERGA, R., PERUZZI, F. & REISS, K. (2003). The IGF-1 receptor in cancer biology. Int. J. Cancer, 107, 873-877.
3. BENNING, C.M. & KYPRIANOU, N. (2002). Quinazoline-derived α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an α1-adrenoceptor-indepedent action. Cancer Res., 62, 597-603.
4. BELLO-DEOCAMPO, D. & TINDALL, D.J. (2003). TGF-β/Smad signaling in prostate cancer. Curr. Drug Targets, 4, 197-207.
5. BERGER, A.P., KOFLER, K., BEKTIC, J., ROGATSCH, H., STEINER, H., BARTSCH, G. & KLOCKER, H. (2003). Increased growth factor prodcution in a human prostatic stromal cell culture model caused by hypoxia. Prostate, 57, 57-65.
6. BHOWMICK, N.A., CHYTIL, A., PLIETH, D., GORSKA, A.E., DUMONT, N., SHAPPELL, S., WASHINGTON, M.K., NEILSON, E.G. & MOSES, H.L. (2004). TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science, 303, 848-850.
7. BOGDANOS, J., KARAMANOLAKIS, D., TENTA, R., TSINTAVIS, A., MILATHIANAKIS, C., MITSIADES, C. & KOUTSILIERIS, M. (2003). Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr. Relat. Cancer, 10, 279-289.
8. BORGSTROM, P., BOURDON, M.A., HILLAN, K.J., SRIRAMARAO, P. & FERRARA, N. (1998). Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumours in vivo. Prostate, 35, 1-10.
9. BRUCKHEIMER, E.M. & KYPRIANOU, N. (2002). Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-β dihydrotestosterone in prostate cancer cells. Prostate, 53, 133-142.
10. CRONAUER, M.V., HITTMAIR, A., EDER, I.E., HOBISCH, A., CULIG, Z., RAMONER, R., ZHANG, J., BARTSCH, G., REISSIGL, A., RADMAYR, C., THURNHER, M. & KLOCKER, H. (1997). Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate, 31, 223-233.
11. DILLIN, A., CRAWFORD, D.K. & KENYON, C. (2002). Timing requirements for insulin/IGF-1 signaling in C. elegans. Science, 298, 830-834.
12. DJAKIEW, D. (2000). Deregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate, 42, 150-160.
13. DJAVAN, B., WALDERT, M., SEITZ, C. & MARBERGER, M. (2001). Insulin-like growth factors and prostate cancer. World J. Urol., 19, 225-233.
14. DORKIN, T.J., ROBINSON, M.C., MARSH, C., BJARTELL, A., NEAL, D.E. & LEUNG, H.Y. (1999). FGF-8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene, 18, 2755-2761.
15. FAHAM, S., LINHARDT, R.J. & REES, D.C. (1998). Diversity does make a difference: fibroblast growth factor-heparin interactions. Curr. Opin. Struct. Biol., 8, 578-586.
16. FENG, X.S. & DERYNCK, R. (2005). Specificity and versatility in TGF-β signaling through Smads. Annu. Rev. Cell Dev. Biol., 21, 659-693.
17. FERRARA, N., GERBER, H.P. & LECOUTER, J. (2003). The biology of VEGF and its receptors. Nat. Med., 9, 669-676.
18. FERRARA, N. & HENZEL, W.J. (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophy. Res. Commun., 161, 851-858.
19. FERRER, F.A., MILLER, L.J., ANDRAWIS, R.I., KURTZMAN, S.H., ALBERTSEN, P.C., LAUDONE, V.P. & KREUTZER, D.L. (1998). Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology, 51, 161-167.
20. FERRER, F.A., MILLER, L.J., LINDQUIST, R., KOWALCZYK, P., LAUDONE, V.P., ALBERTSEN, P.C. & KREUTZER, D.L. (1999). Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology, 54, 567-572.
21. +-ATPase. J. Biol. Chem., 273, 544-551.
22. FU, X.S., CHOI, E., BUBLEY, G.J. & BALK, S.P. (2005). Identification of hypoxia-inducible factor-1α (HIF-1α) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate, 63, 215-221.
23. GARRISON, J.B. & KYPRIANOU, N. (2004). Novel targeting of apoptosis pathways for prostate cancer therapy. Cur. Cancer Drug. Targets, 4, 85-95.
24. GARRISON, J.B. & KYPRIANOU, N. (2006). Doxazosin induces apoptosis of benign and malignant prostate cells via a death-receptor mediated pathway. Cancer Res., 66, 1-9.
25. GERDES, M.J., LARSEN, M., DANG, T.D., RESSLER, S.J., TUXHORN, J.A. & ROWLEY, D.R. (2004). Regulation of rate prostate stromal cell myodifferentiation by androgen and TGF-β1. Prostate, 58, 299-307.
26. GNANAPRAGASAM, V.J., ROBINSON, M.C., MARSH, C., ROBSON, C.N., HAMDY, F.C. & LEUNG, H.Y. (2003). FGF8 isoform b expression in human prostate cancer. Br. J. Cancer, 88, 1432-1438.
27. GOSPODAROWICZ, D. & CHENG, J. (1986). Heparin protects basic and acidic FGF from inactivation. J. Cell. Physiol., 128, 475-484.
28. GRAY, M.J., ZHANG, J., ELLIS, L.M., SEMENZA, G.L., EVANS, D.B., WATOWICH, S.S. & GALLICK, G.E. (2005). HIF-1α, STAT3, CBP/p300 and REF-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene, 24, 3110-3120.
29. GRIMBERG, A. & COHEN, P. (2000). Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell. Phys., 183, 1-9.
30. GUO, Y., JACOBS, S.C. & KYPRIANOU, N. (1997). Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int. J. Cancer, 71, 573-579.
31. GUO, Y. & KYPRIANOU, N. (1999). Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumourigenicity via induction of caspase-1-mediated apoptosis. Cancer Res., 59, 1366-1371.
32. HSING, A.Y., KADOMATSU, K., BONHAM, M.J. & DANIELPOUR, D. (1996). Regulation of apoptosis induced by transforming growth factor-β1 in nontumourigenic and tumourigenic rat prostatic epithelial cell lines. Cancer Res., 56, 5146-5149.
33. ISAACS, J.T. (1994). Role of androgens in prostatic cancer. Vitam. Horm., 49, 433-502.
34. ITTMAN, M. & MANSUKHANI, A. (1997). Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J. Urol., 157, 351-356.
35. 2 sensing. Science, 292, 464-468.
36. 2-regulated prolyl hydroxylation. Science, 292, 468-472.
37. JACKSON, M.W., ROBERTS, J.S., HECKFORD, S.E., RICCIARDELLI, C., STAHL, J., CHOONG, C., HORSFALL, D.J. & TILLEY, W.D. (2002). A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res., 62, 854-859.
38. JIANG, B.H., AGANI, F., PASSANITI, A. & SEMENZA, G.L. (1997). V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumour progression. Cancer Res., 57, 5328-5335.
39. JOHNSON, D.E., LEE, P.L., LU, J. & WILLIAMS, L.T. (1990). Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol. Cell. Biol., 10, 4728-4736.
40. JOSEPH, I.B., NELSON, J.B., DENMEADE, S.R. & ISAACS, J.T. (1997). Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin. Cancer Res., 3, 2507-2511.
41. KANG, H.Y., LIN, H.K., HU, Y.C., YEH, S., HUANG, K.E. & CHANG, C. (2001). From transforming growth factor-β signaling to androgen action: identification of Smad3 as an androgen receptor co-regulator in prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A., 98, 3018-3023.
42. KELEDJIAN, K., GARRISON, J.B. & KYPRIANOU, N. (2005). Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J. Cell. Biochem., 94, 374-388.
43. KHOSRAVI, J., DIAMANDI, A., MISTRY, J. & SCORILAS, A. (2001). Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J. Clin. Endocrinol. Metab., 86, 694-699.
44. KIM, K.J., LI, B., WINER, J., ARMANINI, M., GILLETT, N., PHILLIPS, H.S. & FERRARA, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841-844.
45. KIRBY, R.S. & POOL, J.L. 1997)). α1-Adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br. J. Urol., 80, 521-532.
46. KUBOTA, T., KOSHIZUKA, K., WILLIAMSON, E.A., ASOU, H., SAID, J.W., HOLDEN, S., MIYOSHI, I. & KOEFFLER, H.P. (1998). Ligand for peroxisome proliferator-activated receptor-γ (troglitazone) has potent antitumour effect against human prostate cancer both in vitro and in vivo. Cancer Res., 58, 3344-3352.
47. KYPRIANOU, N. (2003). Doxazosin and Terazosin suppress prostate growth by inducing apoptosis: Clinical significance. J. Urol., 169, 1520-1525.
48. KYPRIANOU, N. & BENNING, C.M. (2000). Suppression of human prostate cancer cell growth by α-1-adrenoreceptor antagonists Doxazosin and Terazosin via induction of apoptosis. Cancer Res., 60, 4550-4555.
49. LARA JR., P.N., TWARDOWSKI, P. & QUINN, D.I. (2004). Angiogenesis-targeted therapies in prostate cancer. Clin. Prostate Cancer, 3, 165-173.
50. LEE, C., SINTICH, S.M., MATHEWS, E.P., SHAH, A.H., KUNDO, S.D., PERRY, K.T., CHO, J.S., ILIO, K.Y., CRONAUER, M.V., JANULIS, L. & SENSIBAR, J.A. (1999). Transforming growth factor-β in benign and malignant prostate. Prostate, 39, 285-290.
51. MCFALL, A., ULKU, A., LAMBERT, Q.T., KUSA, A., ROGERS-GRAHAM, K. & DER, C.J. 2001)). Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinosotol 3-kinase. Mol. Cell. Biol., 21, 5488-5489.
52. MANN, M., HENDRICKSON, R.C. & PANDLEY, A. 2001)). Analysis of proteins and proteomes by mass spectrometry. Ann. Rev. Biochem., 70, 437-473.
53. MANNA, S.K., SAH, N.K., NEWMAN, R.A., CISNEROS, A. & AGGARWAL, B.B. (2000). Oleandrin suppresses activation of nuclear transcription factor-κB, activator protein-1, and c-Jun NH2-terminal kinase. Cancer Res., 60, 3838-3847.
54. MANTZOROS, C.S., TZONOU, A. & SIGNORELLO, L.B. (1997). Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br. J. Cancer, 76, 1115-1118.
55. MASSAGUE, J. (1998). TGF-β signal transduction. Annu. Rev. Biochem., 67, 753-791.
56. MASSAGUE, J., CHEIFETZ, S., LAIHO, M., RALPH, D.A., WEIS, F.M. & ZENTELLA, A. (1992). Transforming growth factor-β. Cancer Surv., 12, 81-103.
57. MASSON, N., WILLAM, C., MAXWELL, P.H., PUGH, C.W. & RATCLIFFE, P.J. (2001). Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J., 20, 5197-5206.
58. 2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res., 60, 3807-3812.
59. MIN, J.H., YANG, H., IVAN, M., GERTLER, F., KAELIN JR., W.G. & PAVLETICH, N.P. (2002). Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science, 296, 1886-1889.
60. MOSCHOS, S.J. & MANTZOROS, C.S. (2002). The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology, 64, 317-332.
61. MOTYL, T. & GAJEWSKA, M. (2004). IGF-binding proteins mediate TGF-β1-induced apoptosis in bovine mammary epithelial BME-UV1 cells. Comp. Biochem. Physiol. C (Toxicol. Pharmacol.), 139, 65-75.
62. MYDLO, J.H., MICHAELI, J., HESTON, W.D. & FAIR, W.R. (1988). Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. Prostate, 13, 241-247.
63. NICKERSON, T., HUYNH, H. & POLLAK, M. (1997). Insulin-like growth factor binding protein-3 induces apoptosis in MCF-7 breast cancer cells. Biochem. Biophysics. Res. Commun., 237, 690-693.
64. NYBERT, P., XIE, L. & KALLUIR, R. (2005). Endogenous inhibitors of angiogenesis. Cancer Res., 65, 3967-3979.
65. ORNITZ, D.M. & ITOH, N. (2001). Fibroblast growth factors. Genome Biol., 2, 3005.1-3005.12.
66. PANIGRAHY, D., SINGER, S., SHEN, L.Q., BUTTERFIELD, C.E., FREEDMAN, D.A., CHEN, E.J., MOSES, M.A., KILROY, S., DUENSING, S., FLETCHER, C., FLETCHER, J.A., HLATKY, L., HAHNFELDT, P., FOLKMAN, J. & KAIPAINEN, A. (2002). PPARγ ligands inhibit primary tumour growth and metastasis by inhibiting angiogenesis. J. Clin. Invest., 110, 923-932.
67. PARTIN, J.V., ANGLIN, I.E. & KYPRIANOU, N. (2003). Quinazoline-based alpha 1-adrenoreceptor antagonists induce prostate cancer cell apoptosis via TGF- β signaling and IκB induction. Br. J. Cancer, 88, 1615-1621.
68. PERRY, K.T., ANTHONY, C.T. & STEINER, M.S. (1997). Immunohistochemical localization of TGF-β1, TGF-β2, and TGF-β3 in normal and malignant human prostate. Prostate, 33, 133-140.
69. REISS, K., D'AMBROSIO, C., TU, X., TU, C. & BASERGA, R. (1998). Inhibition of tumour growth by a dominant negative mutant of the insulin-like growth factor I receptor with the by-stander effect. Clin. Cancer Res., 4, 2647-2655.
70. RENNEBECK, G., MARTELLI, M. & KYPRIANOU, N. (2005). Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res., 65, 11230-11235.
71. ROPIQUET, F., GIRI, D., LAMB, D.J. & ITTMAN, M. (1999). FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J. Urol., 162, 595-599.
72. RYROMAA, M., LEHMAN, K. & DOWNWARD, J. (2000). Matrix detachment induces caspase-dependent cytochrome C release from mitochondria: inhibition by PKB/Akt but not Raf signaling. Oncogene, 19, 4461-4468.
73. SCHER, H.I. & CHUNG, L.W. (1994). Bone metastases: improving the therapeutic index. Semin. Oncol., 21, 630-656.
74. SCHMIDMAIER, G., WILDEMANN, B., OSTAPOWICZ, D., KANDZIORA, F., STANGE, R., HAAS, N.P. & RASCHKE, M. (2004). Long-term effects of local growth factor (IGF-1 and TGF-β1) treatment on fracture healing: A safety study for using growth factors. J. Orthop. Res., 22, 514-519.
75. SEMENZA, G. (2002a). Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol., 64, 993-998.
76. SEMENZA, G.L. (2002b). Involvement of hypoxia-inducible factor 1 in human cancer. Intern. Med., 41, 79-83.
77. SEMENZA, G.L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 3, 721-732.
78. SHARIAT, S.F., KATTAN, M.W., TRAXEL, E., ANDREWS, B., ZHU, K., WHEELER, T.M. & SLAWIN, K.M. (2004). Association of pre-and post-operative plasma levels of transforming growth factor-beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin. Cancer Res., 10, 1992-1999.
79. SHAW, Y.-J., YANG, Y.-T., GARRISON, J.B., KYPRlANOU, N. & CHEN, C.-S. (2004). Pharmacological exploitation of the α1-adrenoreceptor antagonist Doxazosin to develop a novel class of antitumour agents that block intracellular protein kinase B/Akt activation. J. Med. Chem., 47, 4453-4462.
80. SLACK-DAVIS, J.K., EBLEN, S.T., ZECEVIC, M., BOEMER, S.A., TARCAFAIVI, A., DIAZ, H.B., MARCHALL, M.S., WEBER, M.J., PARSON, J.T. & CATLING, A.D. 2003)). PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J. Cell. Biol., 162, 281-291.
81. SMITH, J.A., MADDEN, T., VIJJESWARAPU, M. & NEWMAN, R.A. (2001). Inhibition of the export of fibroblast growth factor-2 (FGF-2) from prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem. Pharmacol., 62, 469-472.
82. SOCIETY AMERICAN CANCER. Cancer Facts and Figures, 2005.
83. SORDELLO, S., BERTRAND, N. & PLOUET, J. (1998). Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem. Biophysic. Res. Commun., 251, 287-290.
84. SROUJI, S., RACHMIEL, A., BLUMENFELD, I. & LIVNE, E. (2005). Mandibular defect by TGF-β and IGF-1 released from a biodegradable osteoconductive hydrogel. J. Craniomaxillofac. Surg., 33, 79-84.
85. STANGELBERGER, A., SCHALLY, A.V., VARGA, J.L., HAMMANN, B.D., GROOT, K., HALMOS, G., CAI, R.-Z. & ZARANDI, M. (2005). Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate, 64, 303-315.
86. STATTIN, P., RINALDI, S., BIESSY, C., STENMAN, U.-H., HALLMANS, G. & KAAKS, R. (2004). High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J. Clin. Oncol., 22, 3104-3112.
87. 3-induced growth inhibition of human prostate cancer cells. Prostate, 64, 9-19.
88. STEWART, R.J., PANIGRAHY, D., FLYNN, E. & FOLKMAN, J. (2001). Vascular endothelial growth factor expression and tumour angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J. Urol., 165, 688-693.
89. 1,-blockers on prostate cancer: a myth or an inviting reality? Prostate, 59, 91-100.
90. TAHMATZOPOULOS, A., ROWLAND, R.G. & KYPRIANOU, N. (2004). The role of α blockers in the management of prostate cancer. Expert. Opin. Pharmacother., 5, 1279-1285.
91. TENNANT, M.K., THRASHER, J.B., TWOMEY, P.A., DRIVDAHL, R.H., BIRNBAUM, R.S. & PLYMATE, S.R. (1996). Protein and messenger ribonucleic acid (mRNA for the type I insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelia. J. Clin. Endocrinol. Metab., 81, 3774-37782.
92. TSANG, M. & DAWID, I.B. (2004). Promotion and attenuation of FGF signaling through the Ras-MAP kinase pathway. Sci. STKE, 228, 317.
93. TU, H., JACOBS, S.C., BORKOWSKI, A. & KYPRIANOU, N. (1996). Significance of apoptosis in prostate cancer progression: relationship with cell proliferation, TGF-β1 and bcl-2 expression. Int. J. Cancer, 69, 357-363.
94. WEI, D., LE, X., ZHENG, L., WANG, L., FREY, J.A., GAO, A.C., PENG, Z., HUANG, S., XIONG, H.Q., ABBRUZZESE, J.L. & XIE, K. (2003). Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene, 22, 319-329.
95. WIENER, J.R., NAKANO, K., KRUZELOCK, R.P., BUCANA, C.D., BAST JR., R.C. & GALLICK, G.E. (1999). Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumour growth in a nude mouse model. Clin. Cancer Res., 5, 2164-2170.
96. WIKSTROM, P., WESTIN, P., STATTIN, P., DAMBER. J.E. & BERGH, A. (1999). Early castration-induced upregulation of transforming growth factor beta-1 and its receptors is associated with tumour cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. Prostate, 38, 268-277.
97. WOLK, A., MANTZOROS, C.S., ANDERSSON, S.O., BERGSTROM, R., SIGNORELLO, L.B., LAGIOU, P., ADAMI, H.O. & TRICHOPOULOS, D. (1998). Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst., 90, 911-915.
98. WU, S.-F., SUN, H.-Z., QI, X.-D. & TU, Z.-H. (2001). Effect of Epristeride on the expression of IGF-1 and TGF-β receptors in androgen-induced castrated rat prostate. Exp. Biol. Med., 226, 954-960.
99. YAMADA, S., TAKETOMI, T. & YOSHIMURA, A. (2004). Model analysis of difference between EGF pathway and FGF pathway. Biochem. Biophys. Res. Commun., 314, 1113-1120.
100. YU, F., WHITE, S.B., ZHAO, Q. & LEE, F.S. (2001). HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. U.S.A., 98, 9630-9635.
101. ZATELLI, M.C., ROSSI, R. & DEGLI UBERTI, E.C. (2000). Androgen influences transforming growth factor-β gene expression in human adrenocortical cells. J. Clin. Endocrinol. Metab., 85, 847-852.
102. ZHU, B. & KYPRIANOU, N. (2005). Transforming growth factor beta and prostate cancer. In: Cytokines and Cancer, ed. Platanias, L. pp. 157-173. New York: Kluwer Academic Publishers.